Background

Levofloxacin inhalation solution is the most recently approved inhaled antibiotic in Europe and Canada for adult cystic fibrosis patients. Its efficacy and safety have been assessed in randomized controlled trials. Our aim was to evaluate real life experience and outcomes in our treatment centre.

Methods

We evaluated the efficacy of inhaled levofloxacin solution in 86 patients with cystic fibrosis in terms of the following outcome parameters: changes in %-predicted forced expiratory volume in one second (FEV₁), body-mass index (BMI), and exacerbation rate. We conducted an intraindividual analysis of patients who received levofloxacin inhalation solution twice daily 240 mg for at least 4 weeks.

Results

Change in FEV₁% predicted for the treatment period was +2.27% (p=0.0027) after 4 weeks. There was no change in BMI for overall group, but exacerbation rate compared to one year before initiation of inhaled levofloxacin decreased significantly (p=0.0024) after 1 year of treatment (3.23 ± 1.39 versus 2.71 ± 1.58).

Conclusions

In patients with cystic fibrosis, inhaled levofloxacin solution has the potential to improve FEV₁ and to reduce the number of bronchopulmonary exacerbations.

中文翻译：

---

真实环境中左氧氟沙星吸入溶液对囊性纤维化患者的临床影响

背景

左氧氟沙星吸入溶液是欧洲和加拿大最近批准用于成人囊性纤维化患者的吸入抗生素。其有效性和安全性已在随机对照试验中得到评估。我们的目的是评估我们治疗中心的真实生活体验和结果。

方法

我们根据以下结果参数评估了吸入左氧氟沙星溶液对 86 名囊性纤维化患者的疗效：预测的一秒用力呼气量 (FEV ₁ )、体重指数 (BMI) 和恶化率的变化。我们对接受每天两次 240 mg 左氧氟沙星吸入溶液至少 4 周的患者进行了个体内分析。

结果

治疗期预测的FEV _{1 % 变化在 4 周后为 +2.27% (p=0.0027)。}整个组的 BMI 没有变化，但与开始吸入左氧氟沙星前一年相比，治疗 1 年后恶化率显着下降（p=0.0024）（3.23 ± 1.39 对 2.71 ± 1.58）。

结论

在囊性纤维化患者中，吸入左氧氟沙星溶液有可能改善 FEV ₁并减少支气管肺恶化次数。